DK1917029T3 - Fremgangsmåde til at behandle cancerceller og skabe en modificeret cancercelle, som provokerer et immunogent respons - Google Patents

Fremgangsmåde til at behandle cancerceller og skabe en modificeret cancercelle, som provokerer et immunogent respons

Info

Publication number
DK1917029T3
DK1917029T3 DK06774696.6T DK06774696T DK1917029T3 DK 1917029 T3 DK1917029 T3 DK 1917029T3 DK 06774696 T DK06774696 T DK 06774696T DK 1917029 T3 DK1917029 T3 DK 1917029T3
Authority
DK
Denmark
Prior art keywords
provokes
creating
immunogenic response
cancer cells
cancer cell
Prior art date
Application number
DK06774696.6T
Other languages
English (en)
Inventor
Moiz Kitabwalla
Hassibullah Akeefe
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK1917029T3 publication Critical patent/DK1917029T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4245—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4273—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
DK06774696.6T 2005-07-27 2006-07-26 Fremgangsmåde til at behandle cancerceller og skabe en modificeret cancercelle, som provokerer et immunogent respons DK1917029T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70269105P 2005-07-27 2005-07-27
PCT/US2006/028933 WO2007016130A2 (en) 2005-07-27 2006-07-26 A method of treating cancer cells to create a modified cancer cell that provokes an immunogenic response

Publications (1)

Publication Number Publication Date
DK1917029T3 true DK1917029T3 (da) 2013-04-29

Family

ID=37709132

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06774696.6T DK1917029T3 (da) 2005-07-27 2006-07-26 Fremgangsmåde til at behandle cancerceller og skabe en modificeret cancercelle, som provokerer et immunogent respons

Country Status (8)

Country Link
US (3) US7361360B2 (da)
EP (2) EP2623116A1 (da)
JP (4) JP2009502933A (da)
CA (1) CA2616344C (da)
DK (1) DK1917029T3 (da)
ES (1) ES2401706T3 (da)
PT (1) PT1917029E (da)
WO (1) WO2007016130A2 (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407662B2 (en) * 2000-06-29 2008-08-05 Lipid Sciences, Inc. Modified viral particles with immunogenic properties and reduced lipid content
US20090017069A1 (en) * 2000-06-29 2009-01-15 Lipid Sciences, Inc. SARS Vaccine Compositions and Methods of Making and Using Them
AUPQ846900A0 (en) * 2000-06-29 2000-07-27 Aruba International Pty Ltd A vaccine
US7407663B2 (en) * 2000-06-29 2008-08-05 Lipid Sciences, Inc. Modified immunodeficiency virus particles
US8608661B1 (en) 2001-11-30 2013-12-17 Advanced Cardiovascular Systems, Inc. Method for intravascular delivery of a treatment agent beyond a blood vessel wall
US7361368B2 (en) 2002-06-28 2008-04-22 Advanced Cardiovascular Systems, Inc. Device and method for combining a treatment agent and a gel
US8821473B2 (en) 2003-04-15 2014-09-02 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
US8383158B2 (en) 2003-04-15 2013-02-26 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
US8038991B1 (en) 2003-04-15 2011-10-18 Abbott Cardiovascular Systems Inc. High-viscosity hyaluronic acid compositions to treat myocardial conditions
US20080125745A1 (en) 2005-04-19 2008-05-29 Shubhayu Basu Methods and compositions for treating post-cardial infarction damage
US9539410B2 (en) 2005-04-19 2017-01-10 Abbott Cardiovascular Systems Inc. Methods and compositions for treating post-cardial infarction damage
US8828433B2 (en) * 2005-04-19 2014-09-09 Advanced Cardiovascular Systems, Inc. Hydrogel bioscaffoldings and biomedical device coatings
DK1917029T3 (da) * 2005-07-27 2013-04-29 Lilly Co Eli Fremgangsmåde til at behandle cancerceller og skabe en modificeret cancercelle, som provokerer et immunogent respons
US7732190B2 (en) * 2006-07-31 2010-06-08 Advanced Cardiovascular Systems, Inc. Modified two-component gelation systems, methods of use and methods of manufacture
US9242005B1 (en) * 2006-08-21 2016-01-26 Abbott Cardiovascular Systems Inc. Pro-healing agent formulation compositions, methods and treatments
US9005672B2 (en) 2006-11-17 2015-04-14 Abbott Cardiovascular Systems Inc. Methods of modifying myocardial infarction expansion
US8741326B2 (en) 2006-11-17 2014-06-03 Abbott Cardiovascular Systems Inc. Modified two-component gelation systems, methods of use and methods of manufacture
US8192760B2 (en) 2006-12-04 2012-06-05 Abbott Cardiovascular Systems Inc. Methods and compositions for treating tissue using silk proteins
PL2591798T3 (pl) 2011-11-09 2015-04-30 Werner Lubitz Szczepionka do zastosowania w immunoterapii nowotworów
EP3195878A1 (en) 2016-01-22 2017-07-26 Werner Lubitz Bacterial ghosts for the treatment of cancer
US12220451B2 (en) 2016-02-04 2025-02-11 Duke University Cell-based vaccine compositions and methods of use
JP7082604B2 (ja) * 2016-03-21 2022-06-08 マレンゴ・セラピューティクス，インコーポレーテッド 多重特異性および多機能性分子ならびにその使用
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
GB2597851B (en) 2019-02-21 2024-05-29 Marengo Therapeutics Inc Antibody molecules that bind to NKP30 and uses thereof
AU2020416273A1 (en) 2020-01-03 2022-07-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
WO2022115433A1 (en) * 2020-11-25 2022-06-02 Xilis, Inc. Micro-organospheres for use in personalized medicine and drug development

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0665297B2 (ja) * 1985-11-01 1994-08-24 小野 啓郎 新規細胞株
KR100363587B1 (ko) * 1999-11-12 2002-12-06 이시우 대식세포와 종양세포의 융합에 의한 항종양 세포성 치료제
WO2001062902A1 (en) 2000-02-27 2001-08-30 Eberhard-Karls-Universität Tübingen Universitätsklinikum Hybrid cell vaccines
US7407663B2 (en) 2000-06-29 2008-08-05 Lipid Sciences, Inc. Modified immunodeficiency virus particles
AUPQ846900A0 (en) 2000-06-29 2000-07-27 Aruba International Pty Ltd A vaccine
US7439052B2 (en) 2000-06-29 2008-10-21 Lipid Sciences Method of making modified immunodeficiency virus particles
US7407662B2 (en) 2000-06-29 2008-08-05 Lipid Sciences, Inc. Modified viral particles with immunogenic properties and reduced lipid content
US20090017069A1 (en) 2000-06-29 2009-01-15 Lipid Sciences, Inc. SARS Vaccine Compositions and Methods of Making and Using Them
CU23002A1 (es) 2000-12-01 2004-11-18 Ct Ingenieria Genetica Biotech Método de obtención de agregados antigénicos y su uso en formulaciones
US20030127386A1 (en) 2001-06-25 2003-07-10 Bomberger David C. Hollow fiber contactor systems for removal of lipids from fluids
US6991727B2 (en) 2001-06-25 2006-01-31 Lipid Sciences, Inc. Hollow fiber contactor systems for removal of lipids from fluids
US20060060520A1 (en) 2001-06-25 2006-03-23 Bomberger David C Systems and methods using a solvent for the removal of lipids from fluids
US7033500B2 (en) 2001-06-25 2006-04-25 Lipid Sciences, Inc. Systems and methods using multiple solvents for the removal of lipids from fluids
WO2003000373A1 (en) 2001-06-25 2003-01-03 Lipid Sciences, Inc. Systems and methods using a solvent for the removal of lipids from fluids
AU2003268190B2 (en) 2002-08-26 2008-04-03 Eli Lilly And Company Treating Alzheimers using delipidated protein particles
PL1567188T3 (pl) * 2003-06-20 2012-12-31 Lilly Co Eli Zmodyfikowane cząstki wirusa o właściwościach immunogennych i zmniejszonej zawartości lipidów użyteczne do leczenia i profilaktyki chorób zakaźnych
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
JP2007527387A (ja) * 2003-07-03 2007-09-27 リピッド サイエンシーズ，インコーポレイテッド 脂質含量の低下したｈｄｌの粒子誘導体を製造するための方法及び装置
DK1917029T3 (da) * 2005-07-27 2013-04-29 Lilly Co Eli Fremgangsmåde til at behandle cancerceller og skabe en modificeret cancercelle, som provokerer et immunogent respons

Also Published As

Publication number Publication date
WO2007016130A2 (en) 2007-02-08
CA2616344A1 (en) 2007-02-08
US8435531B2 (en) 2013-05-07
JP2009242420A (ja) 2009-10-22
US7361360B2 (en) 2008-04-22
US7740872B2 (en) 2010-06-22
EP1917029B1 (en) 2013-01-23
US20070026006A1 (en) 2007-02-01
WO2007016130A3 (en) 2009-04-30
JP2009001577A (ja) 2009-01-08
CA2616344C (en) 2010-10-12
JP2013116925A (ja) 2013-06-13
US20080187559A1 (en) 2008-08-07
EP1917029A2 (en) 2008-05-07
ES2401706T3 (es) 2013-04-23
EP2623116A1 (en) 2013-08-07
JP2009502933A (ja) 2009-01-29
US20100215698A1 (en) 2010-08-26
PT1917029E (pt) 2013-03-13
EP1917029A4 (en) 2010-07-07

Similar Documents

Publication Publication Date Title
EP1944358A4 (en) APPARATUS, METHOD, SOFTWARE AND CELL CULTURE SYSTEM
EG25108A (en) Washing apparatus and washing method for solar panels.
DK2044120T3 (da) Antistoffer, der genkender en kulhydratholdig epitop på cd-43 og cea eksprimeret på cancerceller, og fremgangsmåder til anvendelse deraf
EP1854219A4 (en) METHOD, APPARATUS AND SYSTEM FOR TRANSMITTING ENERGY
GB2440701B8 (en) Method and system for collecting cells following laser microdissection.
DK1896564T3 (da) Fremgangsmåde og indretning til celledyrkning ved hjælp af bølgebevægelse
EP1896368A4 (en) METHOD AND DEVICE FOR THE AUTOMATED, MODULAR GENERATION OF BIOMASS ELECTRICITY
EP1866868A4 (en) Album generating apparatus, album generating method and program
IL191556A0 (en) Solar system and method for the operation thereof
EP1866869A4 (en) Album generating apparatus, album generating method and program
DK2186269T3 (da) Systemniveauinformation til diskontinuert modtagelse, cellegenvalg og RACH
IL185798A0 (en) Pharmacological, chemical and topical agent enhancement apparatus and method for using same
DE602006014096D1 (de) Sprachverarbeitungsverfahren und -einrichtung, Speichermedium und Sprachsystem
EP1865541A4 (en) Exposure method, exposure apparatus and device manufacturing method
PT1917029E (pt) Um método de tratamento de células cancerígenas para criar uma célula cancerígena modificada que provoca uma resposta imunogénica
EP2057811A4 (en) Apparatus for generating down link signal, and method and apparatus for cell search in cellular system
NL1036277A1 (nl) Lithographic apparatus, stage system and stage control method.
NO20051559D0 (no) System og fremgangsmate for utnyttelse av energi
BRPI0717469A2 (pt) Cultura de células vero, e, método para propagar um vírus em células vero.
NL1032675A1 (nl) Bestralingswerkwijze en apparaat voor onderdompelingslithografie.
NO20051931D0 (no) Anordning og fremgangsmate for tilstandskontroll.
NO20040756L (no) Fremgangsmate og system for a etablere samsvar og sporbarhet mellom vaffere og solceller
ZA200609711B (en) Process for uranium recovery
DK1915884T3 (da) Fremgangsmåde til betjening af en kommunikationsindretning og et kommunikationssystem, en kommunikationsindretning og et system, som indbefatter kommunikationsindretningen
NO20055865L (no) Fremgangsmate og anordning ved elektrolysecelle